Gastric Cancer Adenocarcinoma Metastatic Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting gastric cancer adenocarcinoma metastatic clinical trials across 7 countries. Studies span Phase 2, Phase 1. Top locations include Seoul, South Korea, Beijing, Beijing Municipality, China, Beverly Hills, California, United States. Updated daily from ClinicalTrials.gov.


Gastric Cancer Adenocarcinoma Metastatic Trials at a Glance

7 actively recruiting trials for gastric cancer adenocarcinoma metastatic are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Seoul, Beijing, and Beverly Hills. Lead sponsors running gastric cancer adenocarcinoma metastatic studies include Bolt Biotherapeutics, Inc., Dai, Guanghai, and Asan Medical Center.

Browse gastric cancer adenocarcinoma metastatic trials by phase

Treatments under study

About Gastric Cancer Adenocarcinoma Metastatic Clinical Trials

Looking for clinical trials for Gastric Cancer Adenocarcinoma Metastatic? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Cancer Adenocarcinoma Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Cancer Adenocarcinoma Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Phase 2

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai68 enrolled1 locationNCT07392346
Recruiting
Phase 1Phase 2

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Gastroesophageal AdenocarcinomaGastric Cancer Adenocarcinoma Metastatic
Bolt Biotherapeutics, Inc.122 enrolled16 locationsNCT06921837
Recruiting
Phase 2

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Gastric Cancer Adenocarcinoma MetastaticGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Universitaire Ziekenhuizen KU Leuven100 enrolled6 locationsNCT06962137
Recruiting
Phase 1Phase 2

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

Gastric CancerGastric Cancer Adenocarcinoma MetastaticStomach Neoplasm
Asan Medical Center61 enrolled1 locationNCT07149090
Recruiting
Phase 2

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Gastric Cancer Adenocarcinoma Metastatic
LIN YANG31 enrolled1 locationNCT06711471
Recruiting

The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer

Gastric CarcinomaGastric (Cardia, Body) CancerGastric Neoplasm+1 more
Lin Liu112 enrolled1 locationNCT06702683